Observational studyInvestigational new drugs2022

First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study.

Satoshi Igawa et al.PubMed ↗Publisher ↗

No numbers read from the abstract.